您好,欢迎您

肿瘤内科组 薛强 | CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) ……

2022年04月13日

肿瘤内科组 薛强 | CO-STAR:  Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined  with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV  gastric cancer (GC).    

天津医科大学肿瘤医院 胃部肿瘤科    

相关阅读